Skip to main content

CASE REPORT article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1458686

Case Report: Diagnosis of Impaired Consciousness in a Cancer Patient Using Immune Checkpoint Inhibitors

Provisionally accepted
Daniel Cathalifaud Daniel Cathalifaud 1,2*Cristóbal Basáez Cristóbal Basáez 1Tatiana Yáñez Tatiana Yáñez 1,2*
  • 1 Pontificia Universidad Católica de Chile, Santiago, Chile
  • 2 Hospital Clínico de la Universidad Católica, Santiago, Santiago Metropolitan Region (RM), Chile

The final, formatted version of the article will be published soon.

    Immune checkpoint inhibitors (ICIs) are drugs that are being increasingly used in the field of oncology; due to their mechanism of action, they can present immune-related adverse effects (IRAEs), with various clinical manifestations, one of which is delirium. We present the case of a patient diagnosed with pleural mesothelioma that started combined palliative immunotherapy two months before admission. She was hospitalized for delirium with psychotic symptoms and a comprehensive neurological and etiological examination for this pathology was performed, revealing undetectable TSH levels, indicating the etiology of the condition as thyrotoxicosis in the context of autoimmune thyroiditis, secondary to treatment with ICIs. Symptomatic treatment with beta-blockers was initiated, leading to progressive improvement. This case brings awareness of impaired consciousness and neuropsychiatric symptoms as manifestation of IRAEs and the difficulty of their diagnosis: there may also be several other causes of impaired consciousness, so the characterization of delirium requires a multifaceted approach to determine the underlying cause, taking into account direct cancer-related complications and those stemming from the treatments received by these group of patients. Endocrinological immune-related adverse events (IRAEs), such as thyroid IRAEs, generally have a low lethality rate, do not necessarily require discontinuation of therapy, and are linked to a more favorable oncological prognosis. Conversely, neurological IRAEs, though rare, constitute a contraindication for further use of ICIs. This clinical case emphasizes the importance of the systematic study of consciousness impairment in cancer patients, and of considering multiple IRAEs that could lead to changes in oncological therapy when establishing possible etiologies.

    Keywords: Immune checkpoint inhibitor, Delirium, Psychoses, Hyperthyroidism, Thyrotoxicosis, Mesothelioma

    Received: 02 Jul 2024; Accepted: 15 Jan 2025.

    Copyright: © 2025 Cathalifaud, Basáez and Yáñez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Daniel Cathalifaud, Pontificia Universidad Católica de Chile, Santiago, Chile
    Tatiana Yáñez, Pontificia Universidad Católica de Chile, Santiago, Chile

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.